We use cookies so our web site can function correctly. By clicking "OK" or by clicking into any content on this site, you agree to allow cookies to be placed.

Privacy Statement

A cookie is a small file which asks permission to be placed on your computer's hard drive. Once you agree, the file is added and the cookie helps analyse web traffic or lets you know when you visit a particular site. Cookies allow web applications to respond to you as an individual. The web application can tailor its operations to your needs, likes and dislikes by gathering and remembering information about your preferences.

We use traffic log cookies to identify which pages are being used. This helps us analyse data about web page traffic and improve our website in order to tailor it to customer needs. We only use this information for statistical analysis purposes.

Overall, cookies help us provide you with a better website, by enabling us to monitor which pages you find useful and which you do not. A cookie in no way gives us access to your computer or any information about you, other than the data you choose to share with us.

Cookie group mandatory

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms.
You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

These cookies are required


These cookies allow us to adtertise our products to you and allow us to pass this information on to our trusted third parties so that they can advertise our products to you on our behalf
All information these cookies collect is aggregated and therefore anonymous. No personal inforation is shared to third parties. Any personal information collected while using our website could be used for direct marketing from HCA only


These cookies allow us to advertise our products to you and allow us to pass this information on to our trusted third parties so that they can advertise our products to you on our behalf
All information these cookies collect is aggregated and therefore anonymous. No personal inforation is shared to third parties. Any personal information collected while using our website could be used for direct marketing from HCA only

Performance Cookies

These cookies allow us to know which pages are the most and least popular and see how visitors move around the site.  All information collect is annonomas unless you provide personal information to us.
If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.

Brain tumours

Adult brain tumours

Several thousand people are diagnosed with brain tumours in the UK each year. Brain tumours originate from the brain and its surroundings (called primary brain tumours), or arise as secondary deposits of other cancers developing elsewhere in the body (called metastases). Whereas primary brain tumours can arise pretty much from every cell type existent in the brain (with different occurrence rate), only certain cancers are associated with brain metastases.

A detailed list of brain tumours and their classification that can be found here


This is generic term that refers to a large group of tumours deriving from cells that exist within the brain. Depending on the cell of origin, gliomas are called astrocytomas, oligodendrogliomas, ependymomas etc. The cellular origin of gliomas defines their clinical manifestation, radiological appearance and prognosis. Despite these differences gliomas are similar in their ability to invade the brain parenchyma, and as a result, they do not have well defined margins to separate them from the brain. During operations, even if we can see visible margins of these tumours under the microscope, we do know that tumour cells extend well beyond these visible tumour margins. This common feature of gliomas is important when surgical strategies and postoperative oncological treatments are decided.

Apart from the cell type they originate from; the prognosis of gliomas is also defined by the WHO grade of the tumour. Brain tumours and so gliomas are classified by the World Health Organisation (WHO) in 4 grades on the basis of how aggressively they behave. The higher the grade the more aggressive a brain tumour is.

Gliomas of a lower grade (WHO II) have an inherent potential of transforming to higher grades and become malignant (WHO III or IV). For this reason, it is now common practice for these tumours to be treated proactively early after diagnosis. The prognosis of gliomas also depends on their size and location of the tumour at the time of diagnosis (which dictates the surgical management), the clinical performance of the patient (age, general health, level of consciousness, cognitive function, mobility), and the genetic profile of the tumour.

Gliomas are still incurable tumours. However, advances in surgery, neuro-anaesthesia, brain imaging, and neuro-oncology have led to a better overall prognosis. 

Procedures for gliomas - Craniotomy

Advances in glioma surgery were facilitated by better knowledge of the connectivity networks of the brain, advances in imaging of the brain, improvement of postoperative oncology treatments, and sub-specialisation in neurosurgery. Our current practice aims to achieve maximal safe resection of gliomas and at the same time reduce the impact of surgery on patients.

Conventionally patients have surgery on the basis of a preoperative MRI. However, our team uses advanced preoperative imaging including diffusion tractography (DTI) and functional MRI. The information provided from these extra investigations allow assessment of the risk of surgery especially when tumours are located in an area of the brain that hosts important functions like movement, speech, visual field etc. In such cases awake operations can be carried out so the risk of neurological deficit is minimised as much as possible, and the resection of tumours is maximised as much as possible. If neurological deficit cannot be avoided completely this can be tailored to a degree so the patient’s quality of life is affected as little as possible.

Intraoperative image guidance has also developed further. Currently multimodality imaging allows real-time assessment of the progress of an operation. Cellular markers of malignant cells are now used to identify macroscopically invisible tumour remnants at the end of the operation. The use of this fluorescent substance which is administered orally before the procedure is now a standard requirement for glioma surgery.

When brain gliomas are completely removed brain swelling in the area of the operation is less, patient recovery is faster (usual discharge 48 hours after the operation) and postoperative radiotherapy and chemotherapy are tolerated better and their benefit is maximised. 


Meningiomas are tumours that originate from the covering membranes of the brain. In their majority (around 80%) are benign tumours (WHO I). If benign meningiomas are completely removed surgically they have a very low risk of recurrence. 15 -18% of meningiomas (figure depending on the series) can be what we call atypical meningiomas (WHO II).

These are tumours that may recur even if completely removed. Patients with atypical meningiomas may need several operations for recurrences and even radiotherapy. The benefit of radiotherapy in preventing recurrences of atypical meningiomas is currently being assessed in clinical trials. Rarely meningiomas (1-2%) are cancerous and incurable tumours. These are called malignant meningiomas (WHO III). Malignant meningiomas are treated with surgery and postoperative radiotherapy, but remain incurable. 

Procedures for Meningiomas - Craniotomy

When meningiomas are large and cause symptoms, and/or seen to increase in size on serial scans there is an indication to proceed to an operation to remove the tumour, provided patients are fit to undergo surgery. 

The ideal in meningioma surgery is to remove the tumour completely together with its attachment. This is not always possible. The recurrence rate of meningiomas is known to be related to the volume of the tumour left behind and also to the WHO grade of the tumour. The management of the meningioma left behind depends on the volume of the meningioma left behind and the grade of the meningioma. Even if meningiomas are removed completely they have to be followed up with scans. The frequency and duration of scans depends on the grade of the meningioma. 

Metastatic brain tumours

Metastases are secondary tumour deposits originating from primary cancers elsewhere in the body. They develop in the brain when malignant cells travel in the blood stream and invade the brain. Certain cancers like lung, breast, malignant melanomas, renal, and some gastrointestinal cancers, are well known to be associated with brain metastases. The overall prognosis of patients with brain metastases depends on the stage of the primary cancer, the clinical state of the patient, whether or not treatment options are available for the primary cancer, and the number and location of the brain metastases.

The recurrence rate of resected brain metastases is known to be relatively high and for this reason the combination of surgery with postoperative Gamma Knife is very important. In recent years, there are many oncological treatments available for metastases, and also widely available stereotactic radiosurgery treatments such as Gamma Knife.

Posterior fossa tumours in adults

The posterior fossa is a relatively small compartment of the cranial cavity at the back of the head. It contains important structures of the brain that support vital functions of the human body (brain stem), the cerebellum which supports balance and coordination of movements, and a relatively large brain fluid cavity called 4th ventricle. If a relatively large tumour grows in this crowded compartment of the brain, it can cause significant symptoms (unsteadiness, headache, nausea, vomiting) or even a rapid neurological deterioration (drowsiness, coma).

If remained untreated large posterior fossa tumours can be potentially life threatening because of acute hydrocephalus (due to blockage of the circulation of brain fluids) and/or brain stem compression. Tumours in this part of the brain can be either primary (usually benign and in younger patients) or metastases (usually older patients).

Treatment of tumours in this part of the brain is dictated by well-established priorities. The general principle is elimination of the life-threatening factors first (e.g. accumulation of brain fluids under high pressure, called hydrocephalus) before deciding the definite management of the main pathology. 

Contact The Neurosurgery Centre

To make an appointment with our Neurosurgery Centre at The Wellington Hospital 


020 3811 5631
back to top